Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues ...

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.

Gilead’s potential investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

In this short teaser, BioSpace's Head of Insights Lori Ellis talks to CBER Director Peter Marks and Tom Whitehead, Co-Founder ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...